MEDIFAST INC (MED)vsPDD Holdings Inc. (PDD)
MED
MEDIFAST INC
$12.23
-1.05%
CONSUMER CYCLICAL · Cap: $134.54M
PDD
PDD Holdings Inc.
$85.07
-0.94%
CONSUMER CYCLICAL · Cap: $116.09B
Smart Verdict
WallStSmart Research — data-driven comparison
PDD Holdings Inc. generates 127724% more annual revenue ($442.40B vs $346.10M). PDD leads profitability with a 21.6% profit margin vs -5.8%. PDD appears more attractively valued with a PEG of 0.76. PDD earns a higher WallStSmart Score of 76/100 (B+).
MED
Hold45
out of 100
Grade: D
PDD
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MED.
Margin of Safety
+70.6%
Fair Value
$363.48
Current Price
$85.07
$278.41 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Generating 24.1B in free cash flow
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -10.1% — below average capital efficiency
Revenue declined 34.3%
Weak financial health signals
Earnings declined 14.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : MED
The strongest argument for MED centers on Price/Book, Debt/Equity, Altman Z-Score. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bull Case : PDD
The strongest argument for PDD centers on P/E Ratio, Debt/Equity, Free Cash Flow. Profitability is solid with margins at 21.6% and operating margin at 18.4%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : MED
The primary concerns for MED are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : PDD
The primary concerns for PDD are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
MED profiles as a turnaround stock while PDD is a mature play — different risk/reward profiles.
MED carries more volatility with a beta of 0.66 — expect wider price swings.
PDD is growing revenue faster at 11.0% — sustainability is the question.
PDD generates stronger free cash flow (24.1B), providing more financial flexibility.
Bottom Line
PDD scores higher overall (76/100 vs 45/100), backed by strong 21.6% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MEDIFAST INC
CONSUMER CYCLICAL · PERSONAL SERVICES · USA
Medifast, Inc. manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutrition products in the United States and Asia-Pacific. The company is headquartered in Baltimore, Maryland.
Visit Website →PDD Holdings Inc.
CONSUMER CYCLICAL · INTERNET RETAIL · China
Pinduoduo Inc., operates an electronic commerce platform in the People's Republic of China. The company is headquartered in Shanghai, the People's Republic of China.
Visit Website →Compare with Other PERSONAL SERVICES Stocks
Want to dig deeper into these stocks?